2012 Updates on Management of Contrast Induced AKI —— Guidelines & New Evidences Prof. Ben He MD PhD FACC Shanghai Renji Hospital Shanghai Jiaotong University.

Slides:



Advertisements
Similar presentations
Prevention of Contrast-Induced Nephropathy (CIN) Sepehr Khashaei, MD Assistant professor Department of Internal Medicine.
Advertisements

Renal Protection for Coronary Angiography in Advanced Renal Failure Patients by Prophylactic Hemodialysis Presented by Mike Touchy, HO-I.
REMEDIAL II Renal Insufficiency Following Contrast Media Administration Trial II (REMEDIAL II): RenalGuard™ System In High-Risk Patients for Contrast-Induced.
Sodium Bicarbonate for the Prevention of Contrast Induced Nephropathy: A Meta-analysis of Published Clinical Trials Vijayalakshmi Kunadian 1,2, Azfar Zaman.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Can we prevent myocardial and renal revascularization injury? Preventive effect of trimetazidine MR on myocardial and renal injury in diabetic patients.
Perspective on COMMIT/CCS-2 Trial of Metoprolol in STEMI Christopher Cannon, M.D. Brigham and Women’s Hospital Boston, MA.
The Vexing Problem of Vasoplegia
Randomized Angioplasty Beta Blocker Intracoronary Trial II (RABBIT II) Presented at The American Heart Association Scientific Session 2006 Presented by.
Early high-dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome The PRATO-ACS (Protective effect of Rosuvastatin and.
Contrast Induced Nephropathy: Predictors, Prevention, and Management Columbia University Medical Center Cardiovascular Research Foundation Roxana Mehran,
Appendix: Clinical Guidelines VBWG. I Intervention is useful and effective III Intervention is not useful or effective and may be harmful A Data derived.
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
臨床藥事照護 年 09 月其他之用藥建議 疑問藥物問題內容後續追蹤 Actein qid 2 包非正常使用 dose FOR CKD 病人的腎臟 保護 2 文獻資料資料來源 Prophylactic oral administration of the antioxidant.
Network Meta-analyses a novel way for synthetic reviews. 黃道民.
A Prospective Randomized Trial of Furosemide-Induced High-Volume Diuresis with Matched Hydration Using a Dedicated Device to Prevent Contrast Nephropathy.
强 生 Cordis 学 院 Cordis 百家病例论坛 PCI for patients with Chronic Renal Dysfunction Dr. Liyi First Affiliated Hospital of Sun Yat-sen University.
REMEDIAL II REnal Insufficiency Following Contrast MEDIA Administration II TriaL RenalGuard system in high risk patients for contrast induced acute kidney.
ARMYDA-CIN Trial [Atorvastatin for Reduction of Myocardial Damage during Angioplasty–Contrast-Induced Nephropathy]
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Dick de Zeeuw Department of Clinical Pharmacology University Medical Center Groningen The Netherlands Albuminuria; a tool for measuring non-blood pressure.
Silent Ischemia STABLE CAD
Major Published Clinical Trials in AKI: What do they Really Mean? Michael Zappitelli, MD, MSc Montreal Children's Hospital McGill University Health Centre.
Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.
Major Clinical Trials in AKI Michael Zappitelli, MD, MSc Montreal Children's Hospital McGill University Health Centre.
Bicarbonate-Based Solutions in the Management of Acute Kidney Injury Vania Cecilia Prudencio-Ribera, MD 1 ; Universidad Mayor de San Simón, School of Medicine,
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
Atypical Presentations Patients older than 75: frequently no chest pain ECG in evolution (nonspecific ECG changes) Diabetic patients: commonly no chest.
Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.
A.Rasoolzadeh MD. Contrast induced nephropathy (CIN): A kind of reversible AKI as a rise in serum creatinine (by 25%) during of h after receipt.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Risk Involved with Dual RAAS Blockade in Kidney Disease Source: Bakris GL. Dual RAAS blockade is desirable in kidney disease: Con. Kidney Int. 2010;78:546–549.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
Are the European Practice Guidelines for the Management of Arterial Hypertension (2007) adapted to the old and the frail? Anette Hylen
Sodium Bicarbonate therapy for Prevention of contrast induced nephropathy of contrast induced nephropathy -A Meta-analysis American Journal of Kidney Diseases,
The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.
Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive.
1 CONTRAST - INDUCED ACUTE RENAL INJURY. Acute Renal Failure Nephrotoxic ATN Endogenous Toxins –Heme pigments (myoglobin, hemoglobin) –Myeloma light chains.
Hydration for Contrast-Induced Acute Kidney Injury (CI-AKI) Prevention
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.
Renal Replacement Therapy for Prevention of Contrast- induced Acute Kidney Injury: A Meta-analysis of Randomized Controlled Trials Source Song K, Jiang.
© free-ppt-templates.com 2017 AHA/ACC Focused Update of Valvular Heart Disease Guideline of 2014 DR. OMAR SHAHID TR CARDIOLOGY SZH.
TAVR in Patients With Chronic Kidney Disease
Clinical Outcomes with Newer Antihyperglycemic Agents
Nephrology Journal Club The SPRINT Trial Parker Gregg
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
Heparin Should be the First-line Therapy for Patients with ACS/AMI
Prevention of contrast induced nephropathy
IABP-SHOCK II Score Stratifies Patient Risk in CS after AMI
Early high-dose Rosuvastatin for
Hypertension JNC VIII Guidelines.
Revascularization in Patients With Left Ventricular Dysfunction:
Contrast Awareness: Why and When Do we Worry?
The European Society of Cardiology Presented by Dr. Saman Rasoul
VA Cooperative Studies Program Trial # 578
X RAY KUB for Discussion
The Hidden Cost of Underutilizing PCI for Chronic Total Occlusions
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Regadenoson Use in Chronic Kidney Disease and End-Stage.
Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II)Clinical Perspective by Carlo Briguori, Gabriella Visconti, Amelia Focaccio,
Strategies to Reduce Acute Kidney Injury and Improve Clinical Outcomes After Percutaneous Coronary Intervention: A Subgroup analysis of the Prevention.
Outcomes of Acute Kidney Injury in Neonates
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
An Analysis of the ACUITY Trial Lincoff AM, JACC Intv 2008;1:639–48
These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter 
Presentation transcript:

2012 Updates on Management of Contrast Induced AKI —— Guidelines & New Evidences Prof. Ben He MD PhD FACC Shanghai Renji Hospital Shanghai Jiaotong University (上海交通大学医学院附属仁济医院 何奔)

Epidemiology: Incidence of CI-AKI A survey in Shanghai China.2010 Data from US Am J Cardiol 2004;93:1515–1519 Without Significant Reduction in Past Decade

Prognosis: Circulation. 2012;125: Death MACE+DIALYSIS Poor prognosis, especial for pts with persistent renal damage

5 Mechanisms: Direct cytotoxic effects Renal haemodynamics Renal tubulodynamics Regional hypoxia European Heart Journal (2012) 33, 2007– Key Factors:

Important Updates on CI-AKI Guidelines New Researches

I. Definition Traditional Definition of CI-AKI An increase in SCr by more than 25% or 44 μmol/L in the 3 days following intravascular administration of contrast medium (CM) in the absence of an alternative etiology. Other Definition of CI-AKI An increase in CysC by more than 10% in the 24h following intravascular administration of contrast medium (CM).

New Definition: I. Definition Stage 1: SCr increased 1.5–1.9 times baseline SCr increase >0.3mg/dl (26.5 μmol/l) Urinary output < 0.5ml/kg/h during a 6 hour block Stage 2: SCr increase 2.0–2.9 times baseline Urinary output <0.5ml/kg/h during two 6 hour blocks Stage 3: SCr increase >3 times baseline SCr increases to >4.0mg/dl (353 μmol/l) Initiation of renal replacement therapy Urinary output <0.3ml/kg/h during more than 24 hours Anuria for more than 12 hours

New criterior increase sen and sep ? Am Heart J 2012;163: Which definition is better? We need further studies!

Balancing the risk for CIN against the benefit of administering contrast. (Not Graded) Considering alternative imaging methods not requiring contrast administration in patients at increased risk for CIN, so long as these yield the same diagnostic accuracy. (Not Graded) II. Risks Assessment 2011 PCI guideline

11 Mehran Score is proved to predict long-term outcomes. J Am Coll Cardiol.2004;44:1393–9 Clin. Cardiol. 2013,36, 1, 46–53 Predicting Score: Traditional Methods

Easy for practice Baseline Kidney Function Screening—— MDRD formula is preferred

2011 PCI guideline 3.7

2011 PCI guideline 2.62 Data from China Lower than Western Countries !

New Simple Algorithm: To stratify the risk of CI-AKI Maximum Allowable Contrast dose (MACD) was defined as 5*body weight/SCr Increases the positive predictive value of the Mehran risk score (40.7% vs 8.8%) with the same sensitivity (90.7% vs 83.3%) Catheterization and Cardiovascular Interventions,2013, doi: /ccd.24847

Better Contrast Media: Low- Osmolar vs. Iso- Osmolar CM Data from Chinese Population EuroIntervention 2012;8: PCI guideline 2011 UA/NSTEMI guideline

CKD+DM CKD —— No Difference! EuroIntervention 2012;8:

Among Low- Osmolar CMs: Iohexol vs. Iopamidol vs. Ioversol : No apparent clinical advantage among LOCM agents. Am J Cardiol 2012;109:1594–1599

New Factors Rising Concerns: ACEI or ARB increase the risk of CI-AKI? Am J Kidney Dis. 60(4): Further RCTs are warranted ! Retrospective Study

III. Pharmacological Prevention Volume expansion with either isotonic NS or SB (1A) Oral route for hydration, on the premise that adequate intake of fluid and salt are assured (2C) Oral N-acetyl cysteine (NAC) only in appropriate fluid and salt loading (2D). Not using oral NAC as the only method (1D) Do not suggest using theophylline (2C) Do not recommend using fenoldopam (1B) 2011 PCI guideline

Optimal Hydration Protocol: (A) NS 1 mL/kg/h for at least 12 h prior and after the procedure (B) SB 3 mL/kg for 1 h before and 1 mL/kg/h for 6 h after the procedure (C) SB 3 mL/kg over 20 min before the procedure plus sodium bicarbonate orally (500 mg per 10 kg). European Heart Journal (2012) 33, 2071–2079

22 24 h sodium chloride 0.9% is superior to sodium bicarbonate. A short-term regimen with sodium bicarbonate is non-inferior to a 7 h regimen. Optimal Hydration Protocol: European Heart Journal (2012) 33, 2071–2079

Precise Hydration Renal-Guard System: capable of delivering sterile replacement solution in an amount matched to the volume of urine, avoiding hypovolemia and fluid overload. J Am Coll Cardiol Intv 2012;5:90 –7

Benefit for pts with CKD ! J Am Coll Cardiol Intv 2012;5:90 –7 Pilot RCT with 170 pts

New hydration agent: Promising Results! European Heart Journal doi: /eurheartj/eht009 RCT

2011 UA/NSTEMI guideline 2308pts were randomized to NAC group or placebo New Evidence : ACT trial HR, 0.97; 95% CI, ; P=0.92 NAC: ineffective!

High Dose Statin——no yet accepted by guidelines Meta analysis shows : high dose statin might be effective

New Evidence : ARMYDA-CIN trial NSTEMI patients : totally 120mg atorvastatin within 12 hours prior to PCI Endpoint : CIN% 阿托伐他汀安慰剂组 对比剂肾病发生率 (%) P= Giuseppe Patti, et al. Am J Cardiol, 2011 online Perioperative high-dose statin load to reduce perioperative myocardial infarction has been recognized; Prevention of CIN may be derived from the pleiotropic effects of statins.

29 Circulation. 2005;111: Worry Some - Rosuvastatin Increase the risk of inducing proteinuria and renal function injury - CIN? TRACK-D trial: to eliminate this concern Han YL et al CIT meeting report.

IV. Renal Replacement Therapy Do not recommend using prophylactic intermittent haemodialysis (IHD) or haemofiltration (HF) for the purpose of prevention of CIN only. (1C)

New Evidence : Meta-analysis Risk of CI-AKI: No benefit, Even increase the risk! Among the CKD stage Support current guideline! The American Journal of Medicine Volume 125, Issue 1, January 2012, Pages 66–78.e3

V. Beyond guidelines Protocol: IPC was accomplished by performing 4 cycles of alternating 5-minute inflation and 5-minute deflation of a standard upper-arm blood pressure cuff to the individual’s systolic blood pressure plus 50 mm Hg to induce transient and repetitive arm ischemia and reperfusion. Circulation. 2012;126: Pros:

Ischemic Preconditioning A Pilot RCT Simple procedure but maybe effect!

Precise CM volume injection Automated Contrast Injection Systems Incidence of CI-AKI 9% vs 9% P=0.84 Canadian Journal of Cardiology 29 (2013) No Benefit ! Cons: 1358 pts undergoing CAG and PCI from January 31 to May 31, 2011 Manual vs Automated injection

Summary: Something We Gain A Lot We Still Unknown!

Thank You !